Logo

Novo Nordisk Presents Results of Semaglutide in P-IIIa STEP 4 Trial to Treat Obesity at ENDO 2021

Share this

Novo Nordisk Presents Results of Semaglutide in P-IIIa STEP 4 Trial to Treat Obesity at ENDO 2021

Shots:

  • The P-IIIa STEP 4 trial involves assessing the safety and efficacy of Semaglutide (2.4 mg- SC- qw) vs PBO in adults with obesity for 68wks. The participants who reached the maintenance dose of semaglutide- during a 20wks. run-in period were randomized to either continue treatment with the therapy or switch to PBO for 48wks.
  • Results: mean weight loss of 7.9% from week 20 to 68; patients regained 6.9% body weight who were switched to PBO; ETD ( -14.8%)- patients lost 17.4% of their weight who stayed on semaglutide throughout 68wks. trial
  • Semaglutide is an analogue of the human GLP-1 hormone- currently under investigation for chronic weight management and is under FDA and EMA’s review

 ­ Ref: PRNewswire | Image: SCRIP Intelligence

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions